Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 1, 1996, Pages 80-85

  Wang, Laurene H ^a   Schultz, Margaret ^a   Weller, Stephen ^a   Smiley, M Lynn ^a   Blum, M Robert ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; THIAZIDE DIURETIC AGENT; VALACICLOVIR;

AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; FEMALE; HERPES VIRUS INFECTION; HUMAN; HUMAN EXPERIMENT; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0030045735     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.1.80     Document Type: Article

References (26)

1. Andrews, E. B., L. E. Derby, A. M. Walker, R. E. Johnson, and R. P. Platt. Postmarketing safety of oral acyclovir. Submitted for publication.
2. Balfour, H. H., Jr., B. Bean, O. L. Laskin, R. F. Ambinder, J. D. Meyers, J. C. Wade, J. A. Zaia, D. Aeppli, L. E. Kirk. A. C. Segreti, and R. E. Keeney. 1983. Acyclovir halts progression of herpes zoster in immunocompromised patients. N. Engl. J. Med. 308:1448-1453.
3. Bean, B., C. Braun, and H. H. Balfour, Jr. 1982. Acyclovir therapy for acute herpes zoster Lancet ii: 118-121.
4. Beutner, K. R., D. J. Friedman, C. Forszpaniak, P. L. Andersen, M. J. Wood, and The International Valaciclovir Zoster Study Group. 1995. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother. 39:1546-1553
5. Biron, K. D., and G. B. Elion. 1980. In vitro susceptibility of varicella zoster virus to acyclovir Antimicrob Agents Chemother. 18:443-447.
6. Blum, M. R., S. H. T. Liao, and P. De Miranda. 1982 Overview of acyclovir pharmacokinetic disposition in adults and children Am. J. Med. 73(Suppl. 1A):186-192.
7. Cobo, M. 1988. Reduction of the ocular complications of herpes zoster ophthalmicus by oral acyclovir. Am. J. Med 85(Suppl 2A):90-93.
8. de Miranda, P., and M. R. Blum. 1983. Pharmacokinetics of acyclovir after intravenous and oral administration. J. Antimicrob. Chemother. 12(Suppl. B):29-37.
9. Gehan, E. A., and S. L. George. 1970. Estimation of human body surface area from height and weight. Cancer Chemother. Rep. 54(Part I):225.
10. Huff, J. C., B. Bean, H. H. Balfour, Jr., O. L. Laskin, J. D. Connor, L. Corey, Y. J. Bryson, and P. McGuirt. 1988. Therapy of herpes zoster with oral acyelovir Am. J. Med. 85(Suppl. 2A):84-89
11. Laskin, O. L., P. de Miranda, D. H. King, D. A. Page, J. A. Longstreth, L. Rocco, and P. S. Lietman. 1982. Effects of probenecid on the pharmacokinetics and elimination of acyclovir in humans. Antimicrob. Agents Chemother. 21:804-807.
12. Loeser, J. D. 1986. Herpes zoster and post-herpetic neuralgia. Pain 25:149-164.
13. Malloy, J. J., and L. M. Lopez. 1988. Management of hypertension and congestive heart failure, p. 223-246. In J. C Delafuente and R. B. Stewart (ed.). Therapeutics in the elderly. Williams & Wilkins, Baltimore
14. Mawer. G. E., S. B. Lucas, B. R. Knowles, R. M. Stirland, and J. A. Tooth. 1972 Computer assisted prescribing of kanamycin for patients with renal insufficiency. Lancet i:12-15.
15. McKendrick, M. W., J. I. McGill, A, M. Bell, E. Hickmott, and C. Burke. 1984 Oral acyclovir for herpes zoster. Lancet ii:925 (Letter.)
16. Peterslund, N. A., K. Seyer-Hansen, J. Ipsen, V. Esmann, H. Schonheyder, and H. Juhl. 1981 Acyclovir in herpes zoster. Lancet ii:827-830.
17. Quinn, R. P., P. de Miranda, L. Gerald, and S. S. Good. 1979. A sensitive radiuimmunoassay for the antiviral agent BW248U [9-(2-hydroxyethoxymethyl)guanine] Anal Biochem 98:319-328.
18. Ragozzino, M. W., L. J. Melton III, L. T. Kurland, C. P. Chu, and H. O. Perry. 1982. Population-based study of herpes zoster and its sequelae. Medicine 61:310-316.
19. Richards, D. M., A. A. Carmine, R. N. Brogden, R. C. Heel, T. M. Speight, and G. S. Avery. 1983. Acyclovir: a review of its pharmacodynamic properties and therapeutic efficacy. Drugs 26:378-438
20. SHEP Cooperative Research Group. 1991. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265:3255-3264.
21. Shepp, D. H., P. S. Dandliker, and J. D. Meyers. 1986. Treatment of varicella-zoster virus infection in severely immunocompromised patients. N. Engl. J. Med. 314:208-212.
22. Tadepalli, S. M., P. A. Topham, and R. P. Quinn. 1990 Scintillation proximity radioimmunoassay for the measurement of acyclovir. Clin. Chem. 36:1104. (Abstract.)
23. Weller, S., M. R. Blum, M. Doucette, T. Burnette, D. M. Cederberg, P. de Miranda, and M. L. Smiley. 1993. Pharmacokinctics of the acyclovir prodrug valaciclovr after escalating single- and multiple-dose administration to normal volunteers. Clin. Pharmacol. Thcr. 54:595-605
24. Weller, T. H. 1983. Varicella and herpes zoster: changing concepts of the natural history, control and importance of a not-so-benign virus. N. Engl. J. Med. 309:1362-1368. 1434-1440.
25. Whitley, R. J., and J. W. Gnann. 1992. Acyclovir: a decade later N Engl. J. Med. 327:782-789.
26. Wood, M. J. 1986. Herpes zoster in immunocompetent patients. Res. Clin Forums 8:61-68.